Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer

NCT05371197 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

26

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer
Mismatch Repair-deficient (dMMR)
Microsatellite Instability-high (MSI-H)
Neoadjuvant Therapy

Interventions

DRUG: Neoadjuvant therapy with PD-L1 inhibitor

Sponsor

Third Affiliated Hospital, Sun Yat-Sen University